TG: SEC Form 144 filed by Tredegar Corporation

Tredegar Corporation's 10% holder plans to sell 348,189 shares, worth about $2.0M, via NYSE. Previous sales in Aug and Oct 2026 totaled about $2.8M. The stock's historical performance after similar headlines varied, with a median move of 2.2% in either direction.

Original reporting
Published Nov 12, 2026, 7:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TG
Bearish
medium confidence
Mentioned
$TG
Relevance
5/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$TGBearishLow
01

Why it matters

The filing provides new data on insider activity, but the amount is modest.

02

Market read

Provides a small, new data point for traders monitoring TG's share supply.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 6/10Timing: immediate

Background

Form 144 is a notice of proposed sale of restricted securities, often filed by insiders before a public offering.

Company-level read

Ticker impact

$TGBearishMedium confidence
Context

SEC Form 144 filing shows Tredegar Corp plans to sell 348,189 shares (~$2M) in upcoming months.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The disclosed share sale is relatively small but may signal insider confidence and increase supply.

Market effects

Minimal impact on the metal fabrications sector.

Limited to investors tracking TG.

None

Counterpoint

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Tredegar Corporation

    Industrial metal fabrication firm filing the share sale notice.

Related articles

$TGMed

TREDEGAR REPORTS THIRD QUARTER 2026 RESULTS

TREDEGAR CORP (TG) filed an SEC Form 8-K — Results of Operations and Financial Condition. TREDEGAR REPORTS THIRD QUARTER 2026 RESULTS • Net loss from continuing operations of $(2.8) million, or $(0.08) per diluted share, for the third quarter of 2026 compared to net income from continuing operations $7.1 million, or $0.20 per diluted share, for the third quarter of 20

$TGMed

Tredegar Soars on Q2 Financials

Tredegar Corp (NYSE:TG) reported Q2 2026 results for the period ended June 30, 2026. Net income from continuing operations rose to $6.0 million, or $0.17 per diluted share, from $1.8 million, or $0.05 per share, in Q2 2025. Excluding special items, net income was $6.4 million, or $0.18 per share. Aluminum Extrusions EBITDA was $14.5 million versus $9.3 million in Q2 2025.

$TGMed

TREDEGAR REPORTS SECOND QUARTER 2026 RESULTS

TREDEGAR CORP (TG) filed an SEC Form 8-K — Results of Operations and Financial Condition. TREDEGAR REPORTS SECOND QUARTER 2026 RESULTS • Increased second quarter 2026 results, with net income from continuing operations of $6.0 million, or $0.17 per diluted share, for the second quarter of 2026 compared to $1.8 million, or $0.05 per diluted share, for the second quarte

$KNSAMed

Top pharma stock to watch: TD Cowen’s pick

TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.